What's new in HIV/AIDS: Clinical news from the XVI International AIDS Conference: The attempt of a summing up

Infection

Volumn 34, Issue 5, 2006, Pages 294-297

  Julg B ^a   Goebel, F D ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MICROBICIDE; MK 0518; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANADA; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG RESEARCH; HEALTH CARE FINANCING; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTERNATIONAL COOPERATION; REVIEW; SIDE EFFECT; VACCINATION; VIRUS RESISTANCE; ARTICLE; DRUG COMBINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; HUMANS;

EID: 33749839005     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-006-6506-5     Document Type: Review

References (17)

1. Bonnet F, et al: Causes of severe morbidity in HIV-infected patients. Aquitaine cohort 2000-2004: the importance of bacterial infections, cardio-vascular, digestive, and psychiatric morbidity, XVI International AIDS Conference, Toronto 2006, MOPDB02.
2. Triant V, et al: Myocardial infarction rates among HIV-infected patients in a U.S. health care system, XVI International AIDS Conference, Toronto 2006, WEPE0179.
3. Wensing AM: On behalf of the SPREAD-programme - Transmission of HIV drug resistance in Europe, XVI International AIDS Conference, Toronto 2006, TUAB0101.
4. El-Sadr W; for the SMART Study Group: Inferior clinical outcomes with episodic CD4-guided antiretroviral therapy aimed at drug conservation (DC) in SMART study: consistency of finding in all patient subgroups, XVI International AIDS Conference, Toronto 2006, WEAB0204.
5. van Sighem A, et al: Immunological, virological and clinical changes during periods of transient viremia, XVI International AIDS Conference, Toronto 2006, TUPE0003.
6. Riddler SA; for the AIDS Clinical Trials Group 5142 Study Team: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142, XVI International AIDS Conference, Toronto 2006, THLB0204.
7. Eron J, et al: The KLEAN Study: fosamprenavir + ritonavir (FPV/r) versus lopinavir/ritonavir (LPV/r) in antiretroviral-naïve (ARTNaïve) HIV-1 infected adults over 48 weeks, XVI International AIDS Conference, Toronto 2006, THLB0205.
8. Arribas J, et al: Lopinavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: forty eight week results of a randomized, controlled, open label, clinical trial (OK04 Study), XVI International AIDS Conference, Toronto 2006, THLB0203.
9. Delfraissy JF, et al: MONARK Trial (MONotherapy AntiRetroviral Kaletra): 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r + zidovudine/lamivudine (AZT/3TC) in antiretroviral-naïve patients, XVI International AIDS Conference, Toronto 2006, THLB0202.
10. Nunes EP, et al: 48-week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/ml on HAART - the KalMo study, XVI International AIDS Conference, Toronto 2006, TUAB0103.
11. Cameron W, et al: A two-year randomized controlled clinical trial in antiretroviral-naïve subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (Study M03-613), XVI International AIDS Conference, Toronto 2006, THLB0201.
12. Gallant J, et al: Efficacy and safety of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naïve patients, XVI International AIDS Conference, Toronto 2006, TUPE0064.
13. Molina JM, et al: TMC114/r in treatment-experienced HIV patients in power 3: 24-week efficacy and safety analysis, XVI International AIDS Conference, Toronto 2006, TUPE0060.
14. Cohen C, et al: Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223, XVI International AIDS Conference, Toronto 2006, TUPE0061.
15. Mayer H, et al: Safety and efficacy of Maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial, XVI International AIDS Conference, Toronto 2006, THLB0215.
16. Markowitz M, et al: Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naïve HIV-1 infected patients, XVI International AIDS Conference, Toronto 2006, THLB0214.
17. Auvert B, et al: Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2(11): e298. Erratum in: PLoS Med 2006; 3(5): e298.